Stifel Maintains Buy on Candel Therapeutics, Lowers Price Target to $19

Benzinga · 1d ago
Stifel analyst Stephen Willey maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $22 to $19.